Research Topics
| Dietmar SiemannSummaryAffiliation: University of Florida Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Targeting the tumor vasculature: a strategy to improve radiation therapyDietmar W Siemann
Department of Radiation Oncology, Shands Cancer Center, University of Florida, 2000 SW Archer Road, Gainesville, FL 32610, USA
Expert Rev Anticancer Ther 4:321-7. 2004..Indeed, the application of such strategies as adjuvants to conventional radiation treatments offers unique opportunities to develop more effective cancer therapies...
Src-signaling interference impairs the dissemination of blood-borne tumor cellsDietmar W Siemann
Department of Radiation Oncology and Shands Cancer Center, University of Florida, 2000 SW Archer Road, Gainesville, FL 32610, USA
Cell Tissue Res 349:541-50. 2012..The results demonstrate that Src inhibition most effectively interferes with the establishment of secondary tumor deposits when treatments are administered while tumor cells are in the initial phases of dissemination...- Vascular targeted therapies in oncologyDietmar W Siemann
Department of Radiation Oncology, University of Florida, 2000 SW Archer Road, Gainesville, FL, USA
Cell Tissue Res 335:241-8. 2009.... - Dual targeting of tumor vasculature: combining Avastin and vascular disrupting agents (CA4P or OXi4503)Dietmar W Siemann
Department of Radiation Oncology, University of Florida College of Medicine, Gainesville, FL 32610, USA
Anticancer Res 28:2027-31. 2008..This study evaluated the therapeutic efficacy of combining vascular disrupting agents with antiangiogenic agents... - Vascular-targeting therapies for treatment of malignant diseaseDietmar W Siemann
Department of Radiation Oncology, University of Florida, Gainesville, Florida 32610, USA
Cancer 100:2491-9. 2004.... - Therapeutic strategies that selectively target and disrupt established tumor vasculatureDietmar W Siemann
Department of Radiation Oncology, Shands Cancer Center, 2000 SW Archer Road, Gainesville, FL 32610, USA
Hematol Oncol Clin North Am 18:1023-37, viii. 2004..This articles discusses therapeutic strategies that selectively target and disrupt established tumor vasculature... - Efficacy of combined antiangiogenic and vascular disrupting agents in treatment of solid tumorsDietmar W Siemann
Department of Radiation Oncology, Shands Cancer Center, University of Florida, Gainesville, FL, USA
Int J Radiat Oncol Biol Phys 60:1233-40. 2004.... - Differentiation and definition of vascular-targeted therapiesDietmar W Siemann
Department of Radiation Oncology, University of Florida, PO Box 100385, Gainesville, FL 32610, USA
Clin Cancer Res 11:416-20. 2005.... - The vascular disrupting agent ZD6126 shows increased antitumor efficacy and enhanced radiation response in large, advanced tumorsDietmar W Siemann
Department of Radiation Oncology, University of Florida Shands Cancer Center, Gainesville, FL 32610, USA
Int J Radiat Oncol Biol Phys 62:846-53. 2005..The efficacy of ZD6126 was investigated in large vs. small tumors in a variety of animal models... - Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapyDietmar W Siemann
Department of Radiation Oncology, Shands Cancer Center, University of Florida, Gainesville, FL 32610, USA
Int J Cancer 99:1-6. 2002..In addition, the inclusion of the antivascular agents did not increase bone marrow stem cell toxicity associated with these anticancer drugs, thus giving rise to a therapeutic gain... - The vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor cediranib (Recentin; AZD2171) inhibits endothelial cell function and growth of human renal tumor xenograftsDietmar W Siemann
Department of Radiation Oncology, University of Florida, Gainesville, FL 32610, USA
Int J Radiat Oncol Biol Phys 73:897-903. 2009..The goal of this study was to examine the therapeutic potential of the vascular endothelial growth factor (VEGF) signaling inhibitor cediranib in a human model of renal cell carcinoma (Caki-1)... - The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting AgentsDietmar W Siemann
Department of Radiation Oncology, University of Florida College of Medicine, Gainesville, FL, USA
Cancer Treat Rev 37:63-74. 2011..Preclinical studies with the different Tumor-VDA classes have demonstrated key tumor-selective anti-vascular and anti-tumor effects... - Enhancement of radiation therapy by the novel vascular targeting agent ZD6126Dietmar W Siemann
Department of Radiation Oncology, Shands Cancer Center, University of Florida, 2000 SW Archer Road, Box 100385, Gainesville, FL 32610, USA
Int J Radiat Oncol Biol Phys 53:164-71. 2002.... - Impact of tumor cell VEGF expression on the in vivo efficacy of vandetanib (ZACTIMA; ZD6474)Dietmar W Siemann
Department of Radiation Oncology, University of Florida, Gainesville, Florida 32610, U S A
Anticancer Res 29:1987-92. 2009.... - Antitumor efficacy of conventional anticancer drugs is enhanced by the vascular targeting agent ZD6126Dietmar W Siemann
Department of Radiation Oncology, Shands Cancer Center, University of Florida, Gainesville, FL 32606, USA
Int J Radiat Oncol Biol Phys 54:1512-7. 2002.... - Enhancement of radiation therapy by vascular targeting agentsDietmar W Siemann
Department of Radiation Oncology, University of Florida Shands Cancer Center, 2000 SW Archer Road, Gainesville, FL 32610, USA
Curr Opin Investig Drugs 3:1660-5. 2002..The application of such vascular targeting strategies as adjuvants to conventional therapeutics such as radiotherapy, offers unique opportunities to develop even more effective cancer therapies... - A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P)Dietmar W Siemann
Department of Radiation Oncology, University of Florida, 2000 SW Archer Road, Gainesville, FL 32610, USA
Expert Opin Investig Drugs 18:189-97. 2009..Finally, the potential of combining VDAs with antiangiogenic therapies has shown considerable promise in preclinical models and such combinations are now beginning to be evaluated in patients... - Targeting the tumor vasculature: enhancing antitumor efficacy through combination treatment with ZD6126 and ZD6474Wenyin Shi
Department of Radiation Oncology, Shands Cancer Center, University of Florida, Gainesville, FL 32610, USA
In Vivo 19:1045-50. 2005..Such combination therapy may have significant therapeutic benefit even in tumors insensitive to either treatment alone... - Leukemia regression by vascular disruption and antiangiogenic therapyGerard J Madlambayan
Department of Medicine, University of Florida, Gainesville, USA
Blood 116:1539-47. 2010..Together, these data show that OXi4503 alone is capable of regressing AML by a multitargeted mechanism and that the addition of bevacizumab mitigates reactive angiogenesis... - Current development status of small-molecule vascular disrupting agentsDavid J Chaplin
OXiGENE Inc, 230 Third Avenue, Waltham, MA 02451, USA
Curr Opin Investig Drugs 7:522-8. 2006..This review discusses the small-molecule VDAs in clinical development. In addition, the potential for combination therapy with VDAs and traditional anticancer therapies, such as radiation, chemotherapy and anti-angiogenics is described... - Evaluations of vascular disrupting agents CA4P and OXi4503 in renal cell carcinoma (Caki-1) using a silicon based microvascular casting techniqueHoward W Salmon
Department of Radiation Oncology, Shands Cancer Center at the University of Florida, Gainesville, FL, USA
Eur J Cancer 42:3073-8. 2006.... - Preclinical evaluations of therapies combining the vascular targeting agent combretastatin A-4 disodium phosphate and conventional anticancer therapies in the treatment of Kaposi's sarcomaLingyun Li
Department of Pharmacology and Experimental Therapeutics, Shands Cancer Center, University of Florida, Gainesville 32610, USA
Acta Oncol 41:91-7. 2002..Such repeated CA4DP exposures also significantly increased the response of KS xenografts to cisplatin. These findings suggest that CA4DP ought to be considered as a candidate agent for therapeutic evaluation in AIDS-KS patients... - Impact of VEGF expression on the physiological characteristics of clonal cell linesChristina M Norris
Department of Radiation Oncology, Shands Cancer Center, University of Florida, Gainesville, Florida 32610, USA
In Vivo 20:815-21. 2006..CONCLUSION: Since the tumor vascular network can impact the efficacy of anti-cancer therapies, these results suggest that VEGF expression may be important to consider in the treatment of cancer... - Preclinical studies of the novel vascular disrupting agent MN-029Wenyin Shi
Department of Radiation Oncology, Shands Cancer Center, University of Florida, Gainesville, FL 32610, USA
Anticancer Res 25:3899-904. 2005.... - VEGF-associated tyrosine kinase inhibition increases the tumor response to single and fractionated dose radiotherapyWilliam D Brazelle
Department of Radiation Oncology, Shands Cancer Center, University of Florida, Gainesville, FL, USA
Int J Radiat Oncol Biol Phys 65:836-41. 2006..CONCLUSIONS: These studies indicate that ZD6474, when used in conjunction with radiation therapy, has a clear therapeutic advantage, providing a rationale for considering the combination of this agent with radiotherapy in the clinic... - Activity of the vascular targeting agent combretastatin A-4 disodium phosphate in a xenograft model of AIDS-associated Kaposi's sarcomaAmyn M Rojiani
Department of Interdisciplinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, University of South Florida, Tampa, USA
Acta Oncol 41:98-105. 2002..These findings demonstrate not only the marked susceptibility of the KS model to CA4DP but also its potential application in studies related to the pathogenesis and therapy of AIDS-KS... - Gene therapy delivery of endostatin enhances the treatment efficacy of radiationWenyin Shi
Department of Pharmacology and Experimental Therapeutics, University of Florida, Gainesville, FL 32610, USA
Radiother Oncol 66:1-9. 2003..05). CONCLUSION: The delivery of endostatin via rAAV vectors may provide an effective means of enhancing the anti-tumor efficacy of radiation therapy... - In vivo functional differences in microvascular response of 4T1 and Caki-1 tumors after treatment with OXi4503Mamta Wankhede
J Crayton Pruitt Family Department of Biomedical Engineering, University of Florida, Gainesville, FL 32611, USA
Oncol Rep 23:685-92. 2010..The differential responses of these two tumor-types suggest that further investigation of the mechanisms of action of VDAs and individual characterization of tumor VDA-responses may be needed for optimal clinical use of these agents... - Characterizing the tumor response to treatment with combretastatin A4 phosphateBeth A Salmon
Department of Pharmacology and Therapeutics, Shands Cancer Center, University of Florida, Gainesville, FL 32610, USA
Int J Radiat Oncol Biol Phys 68:211-7. 2007..To examine the pathophysiologic impact of treatment with combretastatin A4 phosphate (CA4P) in regions of tumors that ultimately either necrose or survive treatment with this agent... - Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapiesMichael R Horsman
Department of Experimental Clinical Oncology, Aarhus University Hospital, Aarhus, Denmark
Cancer Res 66:11520-39. 2006..This review aims to discuss the pathophysiologic changes induced by VTAs and the implications of these effects on the potential use of VTAs in combined modality therapy... - Augmented antitumor effects of radiation therapy by 4-1BB antibody (BMS-469492) treatmentWenyin Shi
Department of Radiation Oncology, Shands Cancer Center, University of Florida, Gainesville, FL 32610, USA
Anticancer Res 26:3445-53. 2006.... 
BMS-777607, a small-molecule met kinase inhibitor, suppresses hepatocyte growth factor-stimulated prostate cancer metastatic phenotype in vitroYao Dai
Department of Radiation Oncology, University of Florida, Cancer Genetic Research Complex, Room 485E, Gainesville, Florida 32610, USA
Mol Cancer Ther 9:1554-61. 2010....- Support of a free radical mechanism for enhanced antitumor efficacy of the microtubule disruptor OXi4503Lori Rice
Department of Radiation Oncology, University of Florida, Gainesville, FL 32610, USA
Microvasc Res 81:44-51. 2011..These findings indicate that while the predominant in vivo effect of OXi4503 is clearly due to microtubule collapse and vascular shut-down, the formation of toxic free radicals likely contributes to its enhanced potency... - Monitoring the treatment efficacy of the vascular disrupting agent CA4PBeth A Salmon
Department of Pharmacology and Therapeutics, University of Florida, Gainesville, FL, USA
Eur J Cancer 43:1622-9. 2007..However, tumour perfusion correlated (r=0.89, p<0.00001) with CA4P treatment efficacy as measured by necrotic fraction, suggesting that DCE-MRI may have utility in a clinical setting... - Effect of the second-generation vascular disrupting agent OXi4503 on tumor vascularityHoward W Salmon
Department of Radiation Oncology, Shands Cancer Center, University of Florida, Gainesville, Florida 32610, USA
Clin Cancer Res 12:4090-4. 2006..One such agent is the combretastatin A4 disodium phosphate (CA4P) analogue OXi4503 (CA1P)... - Simultaneous targeting of VEGF message and VEGF receptor signaling as a therapeutic anticancer approachWenyin Shi
Department of Radiation Oncology, Shands Cancer Center, University of Florida, Gainesville, FL 32610, USA
Anticancer Res 24:213-8. 2004..Vascular endothelial growth factor (VEGF) is one of the most important factors involved in tumor angiogenesis... - Adeno-associated virus-mediated gene transfer of endostatin inhibits angiogenesis and tumor growth in vivoWenyin Shi
Department of Pharmacology and Experimental Therapeutics, University of Florida, Gainesville, Florida 32610, USA
Cancer Gene Ther 9:513-21. 2002..This endostatin level was sufficient to inhibit tumor cell-induced angiogenesis and to suppress both the initiation and subsequent growth of a human colorectal cancer model... - Radiotherapy alone or combined with carbogen breathing for squamous cell carcinoma of the head and neck: a prospective, randomized trialWilliam M Mendenhall
Department of Radiation Oncology, University of Florida College of Medicine, Gainesville, Florida 32610, USA
Cancer 104:332-7. 2005..The current study was performed to investigate the efficacy of carbogen (95% oxygen [O(2)] and 5% carbon dioxide [CO(2)]) breathing during definitive radiotherapy (RT) to enhance local control... - Impact of the Src inhibitor saracatinib on the metastatic phenotype of a fibrosarcoma (KHT) tumor modelMeiyu Dong
Department of Radiation Oncology, 2033 Mowry Rd Rm 485E, Gainesville, FL 32610, USA
Anticancer Res 30:4405-13. 2010..The aim of the present studies was to examine the impact of an Src inhibitor (saracatinib) on a highly metastatic murine sarcoma cell line (KHT)... - Development of an intramuscular xenograft model of canine osteosarcoma in mice for evaluation of the effects of radiation therapyAlastair R Coomer
Departments of Small Animal Clinical Sciences College of Medicine, University of Florida, Gainesville, FL 32610, USA
Am J Vet Res 70:127-33. 2009..To develop an IM xenograft model of canine osteosarcoma in mice for the purpose of evaluating effects of radiation therapy on tumors... - Comparison of the EF-1 alpha and the CMV promoter for engineering stable tumor cell lines using recombinant adeno-associated virusChristian Teschendorf
Department of Molecular Genetics and Microbiology, College of Medicine, University of Florida, P O Box 100266, JHMHSC, Gainesville, FL 32610, USA
Anticancer Res 22:3325-30. 2002..Silencing of the viral CMV immediate early enhancer promoter can be a problem in certain cell types when engineering stable cell lines... - Targeting the tumor blood vessel network to enhance the efficacy of radiation therapyDietmar W Siemann
Department of Radiation Oncology, University of Florida, Gainesville, FL 32610, USA
Semin Radiat Oncol 13:53-61. 2003..The application of such strategies as adjuvants to conventional radiation treatments offers unique opportunities to develop more effective cancer therapies... - Recombinant adeno-associated and adenoviral vectors for the transduction of pancreatic and colon carcinomaChristian Teschendorf
Department of Molecular Genetics and Microbiology, College of Medicine, University of Florida, Gainesville, FL 32610, USA
Anticancer Res 26:311-7. 2006..Materials and Methods: The transduction efficiency of rAAV2 in pancreatic and colon cancer was compared to that of recombinant adenovirus (rAd) in vitro and in vivo using green fluorescent protein (GFP)... - Expression of pluripotent stem cell reprogramming factors by prostate tumor initiating cellsKyung Mi Bae
Department of Urology Prostate Disease Center, College of Medicine and Flow Cytometry Core Facility, University of Florida, Gainesville, Florida 32610, USA
J Urol 183:2045-53. 2010..We identified a discrete population of stem cell-like tumor cells expressing 5 essential transcription factors required to reprogram pluripotency in prostate tumor cell lines and primary prostate cancer tissue... - Postoperative radiation therapy for squamous cell carcinoma of the head and neckWilliam M Mendenhall
Departments of Radiation Oncology, University of Florida, College of Medicine, Gainesville, FL 32610-0385, USA
Am J Otolaryngol 24:41-50. 2003..CONCLUSION: Patients who have a high likelihood of local-regional recurrence after surgery have improved disease control and survival after postoperative RT... - Oxidative stress regulates expression of VEGFR1 in myeloid cells: link to tumor-induced immune suppression in renal cell carcinomaSergei Kusmartsev
Department of Urology, College of Medicine, University of Florida, Gainesville, FL 32610, USA
J Immunol 181:346-53. 2008..Restoration of immunocompetence in metastatic RCC patients by pharmacological elimination of VEGFR1+ cells may have a significant impact on the therapeutic efficacy of cancer vaccines or other immune-based therapies... - Utility of 19F MRS detection of the hypoxic cell marker EF5 to assess cellular hypoxia in solid tumorsHoward W Salmon
Department of Nuclear and Radiological Engineering, University of Florida, Gainesville, FL 32610, USA
Radiother Oncol 73:359-66. 2004.... - Intrinsic radiosensitivity and repair of sublethal radiation-induced damage in canine osteosarcoma cell linesCourtney L Fitzpatrick
Department of Small Animal Clinical Sciences, College of Veterinary Medicine, University of Florida, Gainesville, FL 32610, USA
Am J Vet Res 69:1197-202. 2008..To characterize the radiosensitivity and capacity for sublethal damage repair (SLDR) of radiation-induced injury in 4 canine osteosarcoma cell lines... - The 93rd Annual Meeting of the American Association for Cancer Research. 6-10 April 2002, San Francisco, California, USAJ Martin Brown
Stanford University, Stanford, California, USA
Expert Opin Pharmacother 3:629-32. 2002..There was a mind-boggling array of choices for those interested in cancer research. This meeting was the largest ever convened on a single disease. We will endeavour to provide some of the highlights of this exciting meeting... - Bone marrow stem and progenitor cell contribution to neovasculogenesis is dependent on model system with SDF-1 as a permissive triggerGerard J Madlambayan
Program in Stem Cell Biology and Regenerative Medicine, University of Florida, Gainesville, Florida, USA
Blood 114:4310-9. 2009..The varied BM contribution seen in different model systems is suggestive of redundant mechanisms governing postnatal neovasculogenesis and provides an explanation for contradictory results observed in the field... - Education and training for radiation scientists: radiation research program and American Society of Therapeutic Radiology and Oncology Workshop, Bethesda, Maryland, May 12-14, 2003C Norman Coleman
Radiation Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, Maryland, USA
Radiat Res 160:729-37. 2003..5) Educate other scientists and the general public on the quantitative, basic, molecular, translational and applied aspects of radiation sciences...
Research Grants
- Combining Anti Angiogenesis Strategies and RadiotherapyDietmar Siemann; Fiscal Year: 2005..We believe that these studies will provide essential insights into the therapeutic utility of employing antiangiogenic treatment strategies as adjuvants to radiotherapy. ..
- ENHANCING RADIATION THERAPY: VASCULAR TARGETING AGENTSDietmar Siemann; Fiscal Year: 2007....
- Combining Anti-Angiogenesis Strategies and RadiotherapyDietmar W Siemann; Fiscal Year: 2010..Experiments are designed to investigate the mechanisms underlying the interaction between such therapies and to develop approaches that would maximize the anti-tumor efficacy of such combined treatments. ..
- RADIATION AND DRUG EFFECTS ON TUMOR CELL SUBPOPULATIONSDietmar Siemann; Fiscal Year: 2001..Ultimately we hope that these approaches can be reliably developed to an extent where the use of human tumor biopsy material may lead to radiotherapy treatments more tailored to the individual patient. ..
- ENHANCING RADIATION THERAPY: VASCULAR TARGETING AGENTSDietmar W Siemann; Fiscal Year: 2010..Experiments are designed to investigate how to deliver such therapies for maximum antitumor efficacy as well as determining the potential of developing predictive indicators of their treatment response. ..